Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Noncovalent Bruton tyrosine kinase inhibitors like pirtobrutinib may be a more effective first-line therapy for chronic ...

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...

We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we ...

INDIANAPOLIS (WISH) — Indianapolis-based pharmaceutical giant Eli Lilly and Co. has committed up to $40 million to Indiana University to expand access to clinical trials and innovative treatments for ...

Experts say we’re in a golden age for treating chronic kidney disease, with new drugs like Ozempic yielding major results. Will dialysis and organ transplants become a thing of the past? A healthy ...

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue. The stock recently ...

The mechanism of GLP-1 agonists is straightforward. They mimic the effects of the naturally occurring hormone, GLP-1, which regulates blood sugar and appetite in the body. While they are highly ...

Eli Lilly & Co.’s stock has reached new highs in recent days, becoming the first pharmaceutical company to hit a $1 trillion valuation. The surge has also lifted the founding family’s private ...

A fresh call from Bernstein has Wall Street doing a double-take. Bernstein just reset Eli Lilly’s price target. Analyst Breen cites talks about GLP-1 catalysts, robust U.S. policy, and promising ...

Philadelphia is about to become the host of the fifth Lilly Gateway Labs, a biotech incubator for early-stage companies backed by Eli Lilly & Co., writes Harold Brubaker for The Philadelphia Inquirer.